Latest News and Press Releases

New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks...

BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...

BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...

BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...

Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1%...

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE...

BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...

SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD...

BEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...